LUMINOUS study sheds light on AMD patient characteristics

Baseline patient data from the largest-ever study conducted in medical retina should help to shed valuable light on the use of ranibizumab in a daily clinical setting, according to Christopher Brand MD at the 17th EURETINA Congress in Barcelona. “The data from the LUMINOUS study will provide long-term evidence on the use of ranibizumab in the real-world setting, and may guide physicians in making treatment decisions to optimise patient outcomes with ranibizumab treatment,” said Dr Brand. The five-year prospective LUMINOUS study enrolled more than 30,000 patients from 494 sites across 43 countries, and was designed to evaluate the long-term effectiveness, safety and treatment patterns associated with ranibizumab treatment in patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularisation (mCNV) in real-world setting. “One of the real values of a study of this size is that it included patients from routine clinical practice with more diverse demographics, ocular baseline characteristics and co-morbidities than usual randomised controlled trials in which difficult to treat patients are excluded,” he said. The data from the LUMINOUS study will help to provide long-term evidence on the use of ranibizumab in the real-world setting and may guide physicians in making treatment decisions to optimise patient outcomes with ranibizumab treatment. “This will hopefully improve vision and quality of life for our patients,” he concluded.